Literature DB >> 12390412

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.

Estrid V S Høgdall1, Claus K Høgdall, Jan Blaakaer, Niels H H Heegaard, Eva Glud, Lise Christensen, Johannes E Bock, Bent Nørgaard-Pedersen, Allan Wiik, Susanne K Kjaer.   

Abstract

The p53 gene, a tumour suppressor gene located on the short arm of chromosome 17 (17p13), is frequently mutated in various human tumours. Accumulation of p53 protein in neoplastic cells and its release following tumour necrosis can lead to development of circulating autoantibodies (AAb) against p53. Earlier studies of ovarian cancer (OC) patients reported different frequencies of p53 AAb and conclusions regarding the clinical and prognostic value of these AAb have not been in agreement. We therefore analysed for the presence of p53 AAb in a total of 227 preoperative serum samples from 193 OC patients and 34 patients with ovarian borderline tumours, and, in addition, serum samples from 86 healthy controls. An enzyme-linked immunosorbent assay (ELISA) was used to measure serum IgG antibodies against p53. The p53 protein used in the assay was produced as a hexahistidine-tagged fusion protein by baculovirus-infected Spodoptera frugiperda cells. Cut-off values for p53 AAb were evaluated, and correlations of p53 AAb with clinical-, biochemical data and survival were examined. We found a low sensitivity for p53 AAb alone, and no major additional effect of the detection rate of CA125 was found. No significant associations were found between p53 AAb and clinical stage, age, histological subtype and radicality after primary surgery. In contrast, we found significantly elevated CA125 levels in p53 AAb-positive patients compared to lower CA125 levels in p53 AAb-negative patients (p=0.003). No significant differences were found between p53 AAb-positive and p53 AAb-negative patients in the univariate and multivariate survival analyses. In conclusion, in a screening study for OC serum p53 AAb levels are of no diagnostic value, even if combined with the tumour marker CA125. The presence of increased serum p53 AAb in patients with diagnosed OC could not be correlated with any clinical data and preoperative serum p53 AAb status had no evident value.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390412     DOI: 10.1034/j.1600-0463.2002.11007805.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  9 in total

Review 1.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

2.  Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.

Authors:  Benjamin Piura; Ettie Piura
Journal:  J Oncol       Date:  2010-01-17       Impact factor: 4.375

3.  p53 autoantibodies, cytokine levels and ovarian carcinogenesis.

Authors:  Miyun Tsai-Turton; Antonio Santillan; Dan Lu; Robert E Bristow; Kwun C Chan; Ie-Ming Shih; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2009-04-26       Impact factor: 5.482

4.  Immunologic aspect of ovarian cancer and p53 as tumor antigen.

Authors:  H W Nijman; A Lambeck; S H van der Burg; A G J van der Zee; T Daemen
Journal:  J Transl Med       Date:  2005-09-15       Impact factor: 5.531

5.  Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.

Authors:  Johannes W Pedersen; Aleksandra Gentry-Maharaj; Alexander Nøstdal; Evangelia-Ourania Fourkala; Anne Dawnay; Matthew Burnell; Alexey Zaikin; Joy Burchell; Joyce Taylor Papadimitriou; Henrik Clausen; Ian Jacobs; Usha Menon; Hans H Wandall
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

Review 6.  Mutant p53 as an Antigen in Cancer Immunotherapy.

Authors:  Navid Sobhani; Alberto D'Angelo; Xu Wang; Ken H Young; Daniele Generali; Yong Li
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

7.  Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.

Authors:  Wei-Lei Yang; Aleksandra Gentry-Maharaj; Archana Simmons; Andy Ryan; Evangelia Ourania Fourkala; Zhen Lu; Keith A Baggerly; Yang Zhao; Karen H Lu; David Bowtell; Ian Jacobs; Steven J Skates; Wei-Wu He; Usha Menon; Robert C Bast
Journal:  Clin Cancer Res       Date:  2017-06-21       Impact factor: 12.531

8.  Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Authors:  Katy Milne; Rebecca O Barnes; Adam Girardin; Melanie A Mawer; Nancy J Nesslinger; Alvin Ng; Julie S Nielsen; Robert Sahota; Eric Tran; John R Webb; May Q Wong; Darin A Wick; Andrew Wray; Elissa McMurtrie; Martin Köbel; Steven E Kalloger; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240

Review 9.  Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.

Authors:  Marica Garziera; Marcella Montico; Ettore Bidoli; Simona Scalone; Roberto Sorio; Giorgio Giorda; Emilio Lucia; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.